Welcome to our dedicated page for Baudax Bio news (Ticker: BXRX), a resource for investors and traders seeking the latest updates and insights on Baudax Bio stock.
Baudax Bio, Inc. (NASDAQ: BXRX) is a specialized pharmaceutical company focused on developing and commercializing innovative products designed to meet the needs of hospital and acute care settings. The company's lead product candidate is an intravenous form of meloxicam, a non-opioid analgesic that has completed Phase III clinical trials for the management of moderate to severe pain. Current research includes Phase IIIB clinical trials aiming to assess opioid consumption, pain intensity, and the length of hospital stay in colorectal and orthopedic surgery patients. These trials also evaluate various pharmacoeconomic parameters.
Beyond meloxicam, Baudax Bio is advancing a pipeline of early-stage product candidates including RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) in Phase I clinical trials, and RP2000, an ultra-short-acting NMBA currently in pre-clinical trials. The company is also developing a reversal agent for these NMBAs and DEX-IN, a proprietary intranasal formulation of dexmedetomidine.
Recently, Baudax Bio announced that the U.S. FDA has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is a next-generation Treg therapy designed to address Hemophilia A patients with FVIII inhibitors effectively.
Founded in 2019 and based in Malvern, Pennsylvania, Baudax Bio continues to push forward with its mission to develop meaningful therapeutic solutions for acute care settings, drawing on robust clinical research and innovative therapeutic approaches.
In Q3 2021, Baudax Bio (NASDAQ:BXRX) reported a significant revenue increase of 40% from Q2 2021 and over 300% from Q3 2020, driven by strong demand for its pain management product ANJESO. The company experienced a 66% growth in sales to new accounts. Despite challenges from COVID-19 impacting elective surgeries, September marked the highest sales month since ANJESO's launch. The clinical phase for the neuromuscular blocking agent BX1000 is complete, with results expected soon. Baudax reported a net loss of $17 million for Q3 2021.
Baudax Bio (NASDAQ:BXRX) will report its Q3 2021 financial results on November 4, 2021, at 8:00 a.m. ET. The management team will host a conference call and webcast to discuss these results and operational highlights. Baudax Bio specializes in acute care pharmaceuticals, notably its product ANJESO, an IV COX-2 preferential NSAID for managing moderate to severe pain. The press release also highlights potential risks including commercialization challenges, regulatory compliance, and financial stability.
MALVERN, Pa., Oct. 5, 2021 – Baudax Bio (NASDAQ:BXRX) announced a corporate presentation at the NobleCon Pain Management Investor Forum on October 7, 2021. The presentation will be available for registered attendees starting at 11:00 a.m. Eastern Time and can be accessed on Baudax's investor website. Baudax Bio focuses on innovative products for acute care settings, including ANJESO, a 24-hour intravenous NSAID for managing moderate to severe pain, along with a pipeline of neuromuscular blocking agents and a proprietary reversal agent.
Baudax Bio (NASDAQ:BXRX) announced the approval of stock options and restricted stock units for 22 new employees. A total of 242,688 stock options and 79,385 restricted units were granted on September 30, 2021, as part of their employment compensation. The options have an exercise price of $0.56 per share and vest over four years. This grant complies with Nasdaq’s Rule 5635(c)(4) regarding inducement grants. Baudax Bio specializes in innovative products for acute care settings, notably the intravenous NSAID ANJESO.
MALVERN, Pa., Sept. 16, 2021 – Baudax Bio, a pharmaceutical company focused on acute care innovations, announced that CEO Gerri Henwood will participate in a virtual fireside chat during the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Sept. 22, 2021, at 1:15 p.m. ET. A live webcast will be accessible on Baudax Bio's investor page, with a replay available for 30 days post-event. Baudax Bio's primary product, ANJESO, is the first 24-hour intravenous COX-2 preferential NSAID used for moderate to severe pain management, alongside a pipeline of other novel pharmaceutical assets.
Baudax Bio, a pharmaceutical company focused on acute care products, announced that Gerri Henwood, the President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The corporate presentation will be available for on-demand listening starting September 13 at 7:00 a.m. ET, accessible on the company's website. Baudax Bio's key product, ANJESO, is a 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain. The company also has a pipeline of innovative pharmaceutical assets.
Baudax Bio (BXRX) reported strong growth in ANJESO® sales for Q2 2021, with total vials sold to end-users matching the entire volume of 2020. Key metrics include a 30% increase in total vials sold and a remarkable 150% rise in sales to new ambulatory surgery centers (ASCs). The company successfully added ANJESO® to over 100 formularies and achieved an 82% success rate at P&T committee meetings. Financially, Baudax reported a net loss of $15.3 million for Q2, compared to $30.4 million in the prior year. The company aims to drive adoption of ANJESO® in acute care settings.
Baudax Bio has adjourned its Special Meeting of Shareholders, set to reconvene on August 11, 2021, to further discuss Proposal 1. This proposal seeks to increase the number of authorized shares from 100 million to 190 million. The adjournment aims to provide shareholders additional time to cast their votes, with the record date for eligible voters remaining as June 2, 2021. Shareholders can vote online or by phone, and previously submitted proxies remain valid for the reconvened meeting.
Baudax Bio, Inc. (NASDAQ:BXRX) will report its second quarter 2021 financial results on August 5, 2021. The management will conduct a conference call at 8:00 a.m. ET to discuss these results and recent operational highlights. Baudax Bio's product ANJESO® is the first intravenous NSAID for managing moderate to severe pain, with a pipeline including novel neuromuscular blocking agents. The company faces risks including the impact of COVID-19 on ANJESO's commercial launch and manufacturing capabilities.
Baudax Bio, Inc. (NASDAQ:BXRX) announced that Institutional Shareholder Services (ISS) recommends shareholders vote "FOR" increasing the authorized shares from 100 million to 190 million. This decision will be discussed at the Special Meeting on July 13, 2021. ISS’s support highlights its significance for Baudax's corporate growth and shareholder base expansion. The recommendation is independent, with no prior business relationship between ISS and Baudax. Shareholders are encouraged to participate in the vote and have access to assistance via Okapi Partners.
FAQ
What is the market cap of Baudax Bio (BXRX)?
What is the primary focus of Baudax Bio, Inc.?
What is Baudax Bio's lead product candidate?
What other products are in Baudax Bio's pipeline?
What recent regulatory milestone has Baudax Bio achieved?
Where is Baudax Bio headquartered?
When was Baudax Bio incorporated?
What is the status of meloxicam's clinical trials?
What is TI-168?
Who can I contact for investor relations information?
Are there any other clinical trials Baudax Bio is involved in?
